The New Frontier - Your weekly science and innovation update - 20th April 2026

This week’s news had a single through-line: sovereignty. The UK is signalling it wants to move faster on the things that are now treated as strategic capabilities, from advanced manufacturing to data infrastructure and AI.

In a more contested, volatile world, Whitehall is framing national security as a question of sovereignty, resilience, and prosperity.

For real estate investors, developers, and occupiers, that shift usually brings two things at once: more public capital and policy support on the one hand, and a sharper focus on delivery on the other. In practice, the premium will accrue to schemes that can offer what these strategic sectors need most.

Splitting the atom and fusion grows up

Recognising that the UK needs to accelerate large-scale clean energy provision to meet growing demand and to build resilience to climate change and challenges to energy security two major initiatives were launched this week.

The National Wealth Fund committed up to £599 million to Rolls-Royce SMR, paired the same day with a two-stage design contract from Great British Energy-Nuclear.  The money anchors the first three reactors at Wylfa on Anglesey. The three reactor units will generate at least 1.4GW of low-carbon electricity. This represents enough clean energy to power approximately three million homes for more than 60 years. The project is expected to support 3,000 construction jobs and another 5,000 spread across the national supply chain.  

The real estate story is broader than Anglesey. Manchester is home to the Rolls-Royce SMR corporate HQ. Other major sites are in Warrington, Derby, and Sheffield. A third serial assembly factory is yet to be sited, with South Yorkshire, Teesside, the North West and Wales in the running.

It is worth noting that our latest Data Centres Report spotlighted that nuclear energy is well positioned to support a more electrified, digital economy because it provides reliable power 24 hours a day, 365 days a year, with relatively low operational emissions. Meeting future demand will require significant expansion. Goldman Sachs estimates that AI-driven electricity needs alone could require up to 90GW of additional nuclear capacity.

Separately, The UK Atomic Energy Authority (UKAEA) used Tuesday to publish its 2026–2030 strategy, alongside the first strategy from its new commercial subsidiary, UK Fusion Energy Ltd. The rollout, at Fusion Fest 2026 in London, follows March's £2.5 billion government fusion strategy. The efforts will be spread across four sites - Culham Campus in Oxfordshire, West Burton in Nottinghamshire, Cumbria, and South Yorkshire. This includes a Diagnostics Centre for Excellence and Robotics Operation Skills Centre.

The UKAEA also published a Global Fusion Guide for SMEs, citing forecasts of over £100 billion flowing into fusion globally between 2026 and 2035.

Fusion is tipped to be a multi-trillion-pound global industry in the second half of the century, and it is at an inflection point in 2026. But getting there involves a set of technical challenges, which span specialist science, novel manufacturing, integrated design, and large-scale infrastructure.

Government money, real manufacturing decisions

Science Secretary Liz Kendall used Tuesday to unveil a fresh tranche of life sciences manufacturing investment, with more than £80 million committed through the Life Sciences Innovative Manufacturing Fund. Accord Healthcare will put £45 million into its Barnstaple site while Norgine will spend £20 million-plus expanding its Hengoed facility in South Wales. Additional commitments cover a new biomanufacturing hub in the Midlands and a spray-drying facility in Haverhill, Suffolk.

The fund has now unlocked £600 million of life sciences manufacturing investment in the first four months of the year, and Kendall expects it to hit £1 billion by summer.

The scheme acts as a reminder of the crucial role that incentives play in driving investment.

A sovereign bet on AI 

On Thursday, the government launched its £500 million Sovereign AI Fund at Wayve's London HQ, alongside a new Sovereign AI Unit that will act as an in-house venture capital operation inside DSIT. Balderton partner James Wise will chair it. Portfolio companies get not just capital but prioritised access to supercomputing capacity (Isambard-AI in Bristol and Dawn in Cambridge), plus procurement channels and regulatory support. The first company to receive investment is AI infrastructure startup Callosum. A further six startups will receive access to the AI Research Resource supercomputer network. The companies are Prima Mente, Cosine, Cursive, Doubleword, Twig Bio and Odyssey.

The choice of Wayve for the launch was not incidental. The London self-driving firm, now valued at $8.6 billion, this week added $60 million from AMD, Arm and Qualcomm Ventures to its February Series D and confirmed that the newly-created British Growth Partnership Fund, backed by pension money from Aegon UK, Cushon and M&G, had made its first investment in the company. Wayve is an exemplar of a UK success story.

The government wants to ensure that the UK is a “maker not taker” and that homegrown AI companies are given the support required to start in Britain, scale here and win globally, instead of seeing world-class ideas leave the UK as soon as they begin to succeed.

Government-backed AI vehicles are a pipeline signal. Track the companies they back, because they are primed to scale-up operations.

London’s AI pull

Two moves made London’s AI gravity harder to ignore. On Monday, OpenAI confirmed its firms permanent London office. On Thursday, Anthropic acquired space in the capital to accommodate up to 800 people. Anthropic cited “an exceptional pool of AI talent” when announcing the move. OpenAI described London as offering “ a unique concentration of world-clasee talent across machine learning and the sciences.” An additional driver for this location pattern is enterprise access. Both firms are rapidly growing their enterprise user bases in Europe.

Faster Medicine: the quieter competitiveness play

The government reported that commercial clinical trial set-up times have fallen to 122 days, down from 169 the year before, comfortably beating the 150-day March 2026 target. £137 million of combined funding now sits behind 35 Commercial Research Delivery Centres, and from April, 20% of NIHR Research Delivery Network funding is performance-linked. This practical effect could present a more compelling case for clinical trials in the UK. This matters because the occupiers that run trials can be meaningful space-takers and often cluster near major NHS trusts.

Small deals, bigger year ahead for London lab market

I’ve crunched the Q1 life sciences data. A few early signals are emerging in London’s lab market. Q1 2026 recorded 22,100 sq ft across five deals, though there is 85,600 sq ft under offer (not all of which is human biotech or med-tech, underscoring the importance of correct classifications to ensure capturing market in its fullest) and 145,000 sq ft of active lab or lab/office requirements which indicates a better year of take-up ahead than 2025.  

Q1 2026 take-up was broadly in line with Q1 2025 which recorded 27,299 sq ft of take-up across five deals with an average deal size of 5,460 sq ft. The average deal size for Q1 was 4,420 sq ft underscoring how small deals are the mainstay of the London lab market now. Notably, the Knowledge Quarter/King’s Cross continues to be the dominant cluster accounting for three of the five deals in this area.  This is testament to the cluster’s deep strengths in innovation as well as the development of product aligned to market needs. 100% of the deals were for fully fitted lab space, indicating that occupiers want to minimise fit-out time and capex.

Epoch Biodesign was the largest deal of the quarter, accounting for 62% of total sq ft taken. This was space taken at Victoria Industrial Estate, which forms part of the WestTech Corridor. Epoch Biodesign, founded in 2019 uses AI to develop an enzyme that aims to aid in the bio-recycling of plastics. The company has 56 employees. The company raised $12 million in later stage VC funding in Q1 2026.

It is also notable that Gilead Sciences acquired 50,000 sq ft of office space at 1 Triton Square.

A quick round up of other strands

Innovate UK opened a £20 million quantum networking competition on Tuesday, part of the ProQure programme announced with last month's £2bn quantum commitment.

The UK Semiconductor Centre launched its new London HQ at the Institute of Physics in King's Cross

Farming Minister Dame Angela Eagle unveiled a £50 million agri-tech package (£8 million government, £40 million private co-investment) backing twelve technologies from robotics to biopesticides, with a further £5 million springboard round for 2026–27.

Sanofi acquired UK-based Biotech firm Vicebio. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, “with potential milestone payments of up to $450 million based on development and regulatory achievements”. 

STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, has raised $56 million Series C financing.